Michael J. Tilby

2.4k total citations
55 papers, 2.0k citations indexed

About

Michael J. Tilby is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael J. Tilby has authored 55 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 21 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Michael J. Tilby's work include Cancer therapeutics and mechanisms (15 papers), DNA Repair Mechanisms (14 papers) and DNA and Nucleic Acid Chemistry (14 papers). Michael J. Tilby is often cited by papers focused on Cancer therapeutics and mechanisms (15 papers), DNA Repair Mechanisms (14 papers) and DNA and Nucleic Acid Chemistry (14 papers). Michael J. Tilby collaborates with scholars based in United Kingdom, United States and Australia. Michael J. Tilby's co-authors include Caroline A. Austin, Elaine Willmore, Barbara W. Durkacz, Nicola J. Sunter, Ian G. Cowell, D. Graham Pearson, Christopher J. Ottley, Alan V. Boddy, Kay Padget and Adrian Frank and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Blood.

In The Last Decade

Michael J. Tilby

52 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael J. Tilby United Kingdom 24 1.3k 661 290 245 236 55 2.0k
Ada Rephaeli Israel 33 1.8k 1.4× 564 0.9× 141 0.5× 269 1.1× 180 0.8× 88 2.7k
Izabela Fokt United States 23 1.4k 1.0× 811 1.2× 151 0.5× 338 1.4× 482 2.0× 65 2.4k
Jürgen Thomale Germany 29 1.7k 1.3× 765 1.2× 231 0.8× 211 0.9× 558 2.4× 76 2.8k
Manon Carré France 27 1.1k 0.8× 675 1.0× 132 0.5× 349 1.4× 278 1.2× 65 2.3k
Jan Hraběta Czechia 23 1.6k 1.2× 606 0.9× 152 0.5× 193 0.8× 273 1.2× 53 2.5k
Ding‐Wu Shen United States 18 1.1k 0.9× 999 1.5× 207 0.7× 313 1.3× 287 1.2× 24 2.1k
Nouri Neamati United States 26 1.1k 0.8× 923 1.4× 104 0.4× 635 2.6× 174 0.7× 50 2.5k
Gregory L. Kucera United States 32 1.4k 1.0× 919 1.4× 113 0.4× 628 2.6× 148 0.6× 73 2.7k
Rajeeva Singh United States 22 872 0.6× 940 1.4× 108 0.4× 247 1.0× 154 0.7× 43 2.0k
Hyo Jin Kang South Korea 32 1.7k 1.3× 476 0.7× 94 0.3× 215 0.9× 360 1.5× 103 2.9k

Countries citing papers authored by Michael J. Tilby

Since Specialization
Citations

This map shows the geographic impact of Michael J. Tilby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Tilby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Tilby more than expected).

Fields of papers citing papers by Michael J. Tilby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Tilby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Tilby. The network helps show where Michael J. Tilby may publish in the future.

Co-authorship network of co-authors of Michael J. Tilby

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Tilby. A scholar is included among the top collaborators of Michael J. Tilby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Tilby. Michael J. Tilby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tilby, Michael J., et al.. (2025). A modular synthesis of azetidines from reactive triplet imine intermediates using an intermolecular aza Paternò–Büchi reaction. Nature Catalysis. 8(9). 939–947. 1 indexed citations
2.
Plummer, Ruth, Richard H. Wilson, Hilary Calvert, et al.. (2011). A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer. 104(4). 593–598. 303 indexed citations
3.
Roberts, Darren L., Kaye J. Williams, R. Cowen, et al.. (2009). Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. British Journal of Cancer. 101(8). 1290–1297. 42 indexed citations
4.
Jobson, Andrew G., Elaine Willmore, Michael J. Tilby, et al.. (2008). Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases. Cancer Chemotherapy and Pharmacology. 63(5). 889–901. 14 indexed citations
5.
Cowell, Ian G., Nicola J. Sunter, Prim B. Singh, et al.. (2007). γH2AX Foci Form Preferentially in Euchromatin after Ionising-Radiation. PLoS ONE. 2(10). e1057–e1057. 183 indexed citations
6.
Veal, Gareth J., Julie Errington, Michael J. Tilby, et al.. (2007). Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. British Journal of Cancer. 96(5). 725–731. 32 indexed citations
7.
Cowell, Ian G., Barbara W. Durkacz, & Michael J. Tilby. (2005). Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. Biochemical Pharmacology. 71(1-2). 13–20. 51 indexed citations
8.
Price, L, Michael J. Tilby, Dianne Ford, et al.. (2005). Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. British Journal of Cancer. 92(9). 1626–1635. 11 indexed citations
9.
Jeyapalan, Jessie C., Gabriele Saretzki, A. Leake, Michael J. Tilby, & Thomas von Zglinicki. (2005). Tumour‐cell apoptosis after cisplat in treatment is not telomere dependent. International Journal of Cancer. 118(11). 2727–2734. 13 indexed citations
10.
Willmore, Elaine, et al.. (2004). Differences in the longevity of topo�II? and topo�II? drug-stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemotherapy and Pharmacology. 53(2). 155–162. 30 indexed citations
11.
Gould, Katherine A., et al.. (2004). p53 Elevation in Relation to Levels and Cytotoxicity of Mono- and Bifunctional Melphalan-DNA Adducts. Molecular Pharmacology. 66(5). 1301–1309. 21 indexed citations
12.
Frank, Adrian & Michael J. Tilby. (2003). Quantification of DNA adducts in individual cells by immunofluorescence: effects of variation in DNA conformation. Experimental Cell Research. 283(2). 127–134. 8 indexed citations
13.
Tilby, Michael J.. (2003). Sensitive Competitive Enzyme-Linked Immunoassay for Quantitation of Modified Bases in DNA. Humana Press eBooks. 80. 329–336.
14.
Willmore, Elaine, Fiona Errington‐Mais, Michael J. Tilby, & Caroline A. Austin. (2002). Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochemical Pharmacology. 63(10). 1807–1815. 33 indexed citations
15.
Cressey, Tim R., Michael J. Tilby, & David R. Newell. (2002). Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. European Journal of Cancer. 38(4). 586–593. 17 indexed citations
16.
McGurk, Claire J., Peter J. McHugh, Michael J. Tilby, Keith Grimaldi, & John A. Hartley. (2001). Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses. Methods in enzymology on CD-ROM/Methods in enzymology. 340. 358–376. 8 indexed citations
17.
18.
19.
Peng, Bo, Martin English, Alan V. Boddy, et al.. (1997). Cisplatin pharmacokinetics in children with cancer. European Journal of Cancer. 33(11). 1823–1828. 40 indexed citations
20.
Tilby, Michael J., et al.. (1995). A monoclonal antibody that recognizes alkali-stabilized melphalan-DNA adducts and its application in immunofluorescence microscopy. Carcinogenesis. 16(8). 1895–1901. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ada Rephaeli Breakdown of academic impact, for papers by Izabela Fokt Breakdown of academic impact, for papers by Jürgen Thomale Breakdown of academic impact, for papers by Manon Carré Breakdown of academic impact, for papers by Jan Hraběta Breakdown of academic impact, for papers by Ding‐Wu Shen Breakdown of academic impact, for papers by Nouri Neamati Breakdown of academic impact, for papers by Gregory L. Kucera Breakdown of academic impact, for papers by Rajeeva Singh Breakdown of academic impact, for papers by Hyo Jin Kang
Rankless by CCL
2026